CD8A and cancer: The rationale for therapeutic vaccines is similar for cancer and for HIV: for both tumors and viruses, genomic heterogeneity limits the efficacy of naturally induced immune responses, and in both diseases, there is compelling evidence revealed by next generation sequencing and advances in bioinformatics to suggest that targeting the CD8+ T cell response to specific epitopes may be beneficial.